Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: Occurrence of leukaemic evolution

British Journal of Haematology

Volumn 123, Issue 3, 2003, Pages 517-521

  De Sanctis, Vitaliana ^a,c   Mazzucconi, Maria Gabriella ^a   Spadea, Antonio ^b   Alfò, Marco ^a   Mancini, Marco ^a   Bizzoni, Luisa ^a   Peraino, Monica ^a   Mandelli, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NONE   (Italy)

Author keywords

Essential thrombocythaemia; Leukaemic evolution; Myeloproliferative disorders; Pipobroman

Indexed keywords

ANAGRELIDE; CYTARABINE; HYDROXYUREA; INTERFERON; MELPHALAN; MERCAPTOPURINE; PIPOBROMAN; TIOGUANINE;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; CANCER RISK; CANCER SURVIVAL; DRUG CHOICE; DRUG EFFICACY; FEMALE; FIRST LINE DRUG THERAPY; HUMAN; INCIDENCE; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SECOND CANCER; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; ALKYLATING AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; PIPOBROMAN; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 0242266434     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04542.x     Document Type: Article

References (25)

1. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. & Boiron, M. (1986) Essential thrombocythaemias: clinical evolutionary and biological data. Cancer, 58, 2440-2447.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukaemia: a report of the French-American- British Cooperative Group. Annals of Internal Medicine, 103, 620-624.
3. Brusamolino, E., Canevari, A., Salvaneschi, L., Merante, S. & Bernasconi, C. (1984) Efficacy trial of pipobroman in essential thrombocythaemia: a study of 24 patients. Cancer Treatment Reports, 68, 1339-1342.
4. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. & Barbui, T. (1995) Hydroxyurea in the treatment of patients with essential thrombocythaemia and high risk of thrombosis. New England Journal of Medicine, 332, 1132-1136.
5. Cox, D.R. (1972) Regression models and life tables (with discussion). Journal of the Royal Statistical Society (B), 34, 187-220.
6. Fenaux, P., Simon, M., Caulier, M.T., Lai, J.L., Goudemand, J. & Bauters, F. (1990) Clinical course of essential thrombocythaemia in 147 cases. Cancer, 66, 549-556.
7. Finazzi, G., Ruggeri, M., Rodeghiero, F. & Barbui, T. (2000) Second malignancies in patients with essential thrombocythaemia treated with busulfan and hydroxyurea: long-term follow-up of a randomized clinical trial. British Journal of Haematology, 110, 577-583.
8. Geller, S.A. & Shapiro, E. (1982) Acute leukaemia as a natural sequel to primary thrombocythaemia. American Journal of Clinical Pathology, 72, 353-356.
9. Hattori, A., Nagayama, R., Kishi, K., Fuse, I., Hanano, M., Takizawa, S., Takeshige, T. & Shibata, A. (1991) Primary thrombocythaemia in Japan: a survey of 225 patients. Leukaemia and Lymphoma, 4, 177-186.
10. Hehlmann, R., Jahn, M., Baumann, B. & Kopcke, W. (1988) Essential thrombocythaemia: clinical, characteristics and clinical course of 61 cases. Cancer, 61, 2487-2496.
11. Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-489.
12. Kessler, C.M., Klein, H.G. & Havlik, R.J. (1982) Uncontrolled thrombocytosis in chronic myeloproliferative disorders. British Journal of Hematology, 50, 157-165.
13. Lazzarino, M., Vitale, A., Morra, E., Gagliardi, A., Bernasconi, P., Torromeo, C., Inverardi, D., Burgio, V., Castello, A. & Bernasconi, C. (1989) Interferon alpha-2b as a treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. British Journal of Haematology, 72, 173-177.
14. Lofvenberg, E. & Wahlin, A. (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. European Journal of Haematolagy, 41, 375-381.
15. Mazzucconi, M.G., Francesconi, M., Chistolini, A., Falcione, E., Ferrari, A., Tirindelli, M.C. & Mandelli, F. (1986) Pipobroman therapy of essential thrombocythaemia. Scandinavian Journal of Haematology, 37, 306-309.
16. Murphy, S., Iland, H., Rosenthal, D. & Laszlo, J. (1986) Essential thrombocythaemia: an interim report from the Polycythaemia Vera Study Group. Seminars in Hematology, 23, 177-182.
17. Murphy, S., Peterson, P., Iland, H. & Laszlo, J. (1997) Experience of Polycythaemia Vera Study Group with essential thrombocythaemia: a final report on diagnostic criteria, survival, and leukaemic transition by treatment. Seminars in Hematology, 34, 29-39.
18. Norusis, M.J. (1993) SPSS for Windows: Advanced Statistics, Release 60. SPSS Inc. Chicago.
19. Passamonti, F., Malerba. L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., Barate', C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. & Lazzarino, M. (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. British Journal of Haematology, 116, 855-861.
20. Petti, M.C., Spadea, A., Avvisati, G., Spadea, T., Latagliata, R., Montefusco, E., Cosenza, M. & Malagnino, F. (1998) Polycythaemia vera treated with pipobroman as single agent: low incidence of secondary leukaemia in a cohort of patients observed during 20 years 1971-91. Leukaemia, 12, 869-874.
21. Schafer, A.I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 1-12.
22. Shibata, K., Shimamoto, Y., Suga, K., Sano, M., Matsuzaki, M. & Yamaguchi, M., (1994) Essential thrombocythaemia terminating in acute leukaemia with minimal myeloid differentiation. A brief review of recent literature. Acta Haematologica, 91, 84-88.
23. Sterkers, Y., Prudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, V., Cauters, F. & Fenaux, P. (1998) Acute myeloid leukaemia and myelodysplastic syndromes following essential thrombocythaemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood, 91, 616-622.
24. Storen, E.C. & Tefferi, A. (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood, 97, 863-866.
25. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Publication no. 38. WHO, Geneva.